Bright Minds Biosciences (DRUG)

Search documents
Bright Minds Biosciences (DRUG) - 2022 Q3 - Quarterly Report
2022-08-14 16:00
Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and nine months ended June 30, 2022 and 2021 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars - Unaudited) | --- | --- | --- | --- | |------------------------------------------------------------|-------|--------------------|----------------------| | As at | Notes | June 30, 2022 | September 30, 2021 | | | | ...
Bright Minds Biosciences (DRUG) - 2022 Q2 - Quarterly Report
2022-05-15 16:00
Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and six months ended March 31, 2022 and 2021 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars - Unaudited) | --- | --- | --- | --- | |----------------------------------------------------|-------|--------------------|----------------------| | As at | Notes | March 31, 2022 | September 30, 2021 | | | | $ | $ ...
Bright Minds Biosciences (DRUG) - 2021 Q4 - Annual Report
2021-12-29 20:51
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol(s) Name of each exchange on which registered Common Shares DRUG The Nasdaq Stock Market LLC FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT ...